Guardant Health Announces FDA Approval And Medicare Coverage For Shield Blood Test, Now Commercially Available As First FDA-Approved Blood Test For Primary Colorectal Cancer Screening
Portfolio Pulse from Benzinga Newsdesk
Guardant Health has announced FDA approval and Medicare coverage for its Shield blood test, which is now commercially available as the first FDA-approved blood test for primary colorectal cancer screening.
August 01, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guardant Health's Shield blood test has received FDA approval and Medicare coverage, making it the first FDA-approved blood test for primary colorectal cancer screening. This approval is likely to boost the company's revenues and market position.
The FDA approval and Medicare coverage for Guardant Health's Shield blood test is a significant milestone. It not only validates the product's efficacy but also opens up a large market of Medicare patients, likely leading to increased adoption and revenue growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100